Eczema: tactics of choice external therapy

Cover Page


Cite item

Full Text

Abstract

The therapeutic effects of synthetic tannins are based on their binding action, as well as on their anti-pruritic, antimicrobial and anti-inflammatory effects. Materials and methods. A clinical study of Neotanin spray, Neotanin lotion (suspension) and Neotanin cream was carried out in 8 clinical centres during the period from June, 2017 to January, 2018. The study had an open and non-comparative character. The study included 68 patients of both sex es aged from 1 month to 80 years suffering from eczema dermatosis in the acute weeping phase, including cases with complications after secondary infections (including eczema elements localized on the face). Before the study, information on the clinical history, demographic data, co-morbidities, physical examination data of the patients was collected. The treatment regimen included 2 stages: 1) Neotanin in the spray or lotion (suspension) form 3–4 times per day during 1–5 days, up to the full drying of eczema elements; 2) Neotanin in the cream form 3 times per day, up to the disappearance of the clinical manifestations of skin dermatosis. The duration of the study ranged from 5 to 14 days: the study was completed when a patient had achieved remission. The criteria for assessing the drug efficacy were as follows: dynamics of subjective complaints, objective assessment of the patient's condition (the presence and severity of clinical symptoms), dynamics of the Dermatology Life Quality Index (DLQI). Results. Neotanin preparations showed a high efficacy in the acute and subacute stages of the inflammatory process as an antipruritic agent. Itching stopped within 5 minutes after the drug application, with the antipruritic effect lasting for an average of 3–4 hours. In 85 % of the patients, marked excoriations were absent on the 3rd day of treatment. Neotanin demonstrated a pronounced anti-inflammatory effect. In 92 % of the patients, the symptoms of erythema and edema were significantly reduced one week after the beginning of treatment, with the manifestations of inflammatory exudation being conclusively decreased. One week following the beginning of treatment, 100 % of the patients demonstrated no oozing lesions. The absence of serious undesirable effects in the patients during the study evidences to the good tolerability and safety of this drug.

About the authors

D. V. Zaslavsky

Saint Petersburg State Pediatric Medical Universit y, Ministry of Health of the Russian Federation

Email: venerology@gmail.com

Denis V. Zaslavsky — Dr. Sci. (Medicine), Professor, Professor of the Department of a Dermatovenereology

Litovskaya str., 2, Saint Petersburg, 194100

Россия

Е. S. Tulenkova

Saint Petersburg State Pediatric Medical Universit y, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Elena S. Tulenkova — Doctor of the Department of Dermatology

Litovskaya str., 2, Saint Petersburg, 194100

Россия

K. N. Monakhov

Pavlov First Saint Petersburg State Medical Universit y, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Konstantin N. Monakhov — Dr. Sci. (Medicine), Professor of the Department of a Dermatovenereology

Pavlov First Saint Petersburg State Medical Universit y, Ministry of Health of the Russian Federation

Россия

N. A. Kholodilova

Pavlov First Saint Petersburg State Medical Universit y, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Natal’ya A. Kholodilova — Cand. Sci. (Medicine), Assistant Professor, Department of a Dermatovenereology

Pavlov First Saint Petersburg State Medical Universit y, Ministry of Health of the Russian Federation

Россия

Yu. S. Kondratieva

Altai Medical State Universit y, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Yuliya S. Kondratieva — Dr. Sci. (Medicine), Head of the Department of a Dermatovenereology and Cosmetology and Immunology

Prospekt Lenina, 40, Barnaul, 656038

Россия

O. B. Tamrazova

People’s Friendship Universit y of Russia

Email: fake@neicon.ru

Ol’ga B. Tamrazova — Dr. Sci. (Medicine), Professor of the Department of a Dermatovenereology

Miklukho-Maklaya str., 6, Moscow, 117198

Россия

O. В. Nemchaninova

Novosibirsk State Medical Universit y, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Оl’ga В. Nemchaninova — Dr. Sci. (Medicine), Professor, Head of the Department of a Dermatovenereology and Cosmetology

Krasny prospect, 52, Novosibirsk, 630091

Россия

M. O. Guliev

Kabardino-Balkarian State University

Email: fake@neicon.ru

Magomed O. Guliev — Cand. Sci. (Medicine), Head of the Department, Associate Professor, Department of Skin and Venereal Diseases

Chernyshevsky str., 173, Nalchik, 360004

Россия

I. L. Shlivko

Privolzhsky Research Medical Universit y, Ministry of Health of the Russian Federation

Author for correspondence.
Email: irshlivko@gmail.com

Irena L. Shlivko* — Dr. Sci. (Medicine), Head of the Department of Skin and Veneral Diseases

pl. Minin and Pozharsky, 10/1, Nizhny Novgorod, 603005

Россия

I. Е. Torshina

Smolensk State Medical Universit y, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Irina E. Torshina — Dr. Sci. (Medicine), MD, Head of the Chair Dermatovenerology, Cosmetology and Additional Vocational Education

Krupskaya str., 28, Smolensk, 214019

Россия

References

  1. Павлов С. Т. Учебник кожных и венерических болезней. Москва: Медицина, 1969:464.
  2. Самцов А. В., Барбинов В. В. Дерматовенерология. Учебник. Санкт-Петербург: Спецлит, 2008:351.
  3. Дарье Ж. Основы дерматологии. Москва; Ленинград: Государственное издательство: 1930:1068.
  4. Гебра Ф. Руководство к изучению болезней кожи. Санкт-Петербург: Издание О. И. Бакста: 1876:781.
  5. Sulzberger M. B., Goodman J. The Relative Importance of Specific Skin Hypersensitivity in Adult Atopic Dermatitis. J.A.M.A. 1936;106:1000.
  6. Malcolm M. Diseases of the Skin. An Outline of the Principles and Practice of Dermatology. London: Cassell and Company, 1903;642.
  7. Sigurdsson V. et al. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol. 2000;27(3):436–440.
  8. Fierro M. T. et al. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome. Dermatology. 2006;213(2):284–292.
  9. Calonje E., Brenn T., Lazar A., McKee P. McKee’s Pathology of the Skin, 4rd ed. Philadelphia: Elsevier-Mosby, 2011:1096.
  10. Haslam E. et al. Astringency and polyphenol protein interactions. In: Romeo JT, ed. Phytochemicals in human health protection, nutrition, and plant defense. 1999:289–319.
  11. Folster-Holst, Eva Latussek. Synthetic Tannins in Dermatology — A Therapeutic Option in a Variety of Pediatric Dermatoses. Pediatric Dermatology. 2007;24(3):296–301.
  12. Puschmann M., Matthies C. Synthetischer Gerbstoff im antipruriginosen und lokalanasthetischen Wirksamkeitstest. Kinderarzt. 1985;16:715–717.
  13. Wiedow O. et al. The effect of tamol on humanmast cell chymase and plasmin. Skin Pharmacol. 1997;10:90–96.
  14. Mrowietz U. et al. Selective inactivation of human neutrophil elastase by synthetic tannin. J Invest Dermatol. 1991;97:529–533.
  15. Folster-Holst R. Indications for tannin therapy in dermatology. European Society for Pediatric Dermatology 8th Congress. Budapest, 2005:31–32.
  16. Mrowietz U., Keine P., Wiedow O. Lokaltherapie mit synthetischem Gerbstoff — Erfahrungen mit einer neuen Anwendungsform. Dt Dermatol. 1995;43:563–569.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Zaslavsky D.V., Tulenkova Е.S., Monakhov K.N., Kholodilova N.A., Kondratieva Y.S., Tamrazova O.B., Nemchaninova O.В., Guliev M.O., Shlivko I.L., Torshina I.Е.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies